Why the study?
Recent prospective data support direct oral anticoagulants in oncology patients, requiring an evaluation of current literature and practical considerations for their use in this high-risk population.
Are direct oral anticoagulants safe and effective for managing venous thromboembolism in oncology patients?
Are direct oral anticoagulants safe and effective for managing venous thromboembolism in oncology patients?
This review highlights practical considerations and recent evidence supporting the safe and effective use of direct oral anticoagulants for venous thromboembolism in cancer patients.
May support DOAC consideration for cancer VTE; leaves open need for larger confirmatory RCTs.
Oncology patients are at a high risk of experiencing venous thromboembolism. Historically, venous thromboembolisms in cancer patients have been managed with low-molecular-weight heparin on the basis of the CLOT trial published in 2003. However, recent prospective data provide evidence for safe and effective direct oral anticoagulant use in this population. The purpose of this review article is to evaluate the current body of literature surrounding direct oral anticoagulant use in the oncology population and to highlight key practical considerations when prescribing these agents for patients with cancer.
No takes yet. Share an insight, caveat, or question.
Duong et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: